Evaluating secukinumab's effectiveness with surgery for hidradenitis suppurativa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to retrospectively analyze the efficacy and safety of secukinumab when used in conjunction with surgical treatment for moderate to severe hidradenitis suppurativa (HS). It focuses on patients aged 18 to 80 years who have been diagnosed with HS and have undergone surgery while receiving secukinumab. The research seeks to provide real-world evidence on the treatment outcomes and safety profile of this combination therapy, addressing the limitations of traditional treatments and the high recurrence rates associated with surgery alone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) HS
2. The diagnosis of HS was confirmed by histopathological examination in the Department of Pathology of our hospital
3. Patients with HS who received secukinumab combined with surgery in the Department of Dermatologic Surgery of our hospital
4. Patients with complete clinical data followed up for at least 1 year

Exclusion Criteria:

1. Patients lost to follow-up
2. Patients with less than one year of follow-up
3. Patients who received additional adjuvant therapy during the follow-up period

Where it's running

• Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Youjun ZHENG
• Email: 19943909917@163.com
• Phone: 1+86 9943909917

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Global health study on hidradenitis suppurativa

  This study tests how people with hidradenitis suppurativa access care and what treatments they receive across different health systems.

  Recruiting University of Zurich · Zurich · NCT07659769

• Secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa

  This trial tests two dosing regimens of secukinumab to see if they can help Chinese adults with moderate to severe hidradenitis suppurativa.

  Recruiting at 10 sites Phase 4 Novartis · Guangzhou, Guangdong and 9 other locations · NCT07489573

• Secukinumab for moderate-to-severe hidradenitis suppurativa

  This study tests whether secukinumab helps adults with moderate-to-severe hidradenitis suppurativa who have not improved with antibiotics, isotretinoin, or TNF inhibitors.

  Recruiting Peking Union Medical College · Beijing, Beijing Municipality · NCT07109765

• Short-term treatment satisfaction with Cosentyx for hidradenitis suppurativa in Saudi Arabia

  This will see if adults in Saudi Arabia with moderate-to-severe hidradenitis suppurativa who start Cosentyx are satisfied with its convenience, safety, and effectiveness after 24 weeks.

  Recruiting at 4 sites Novartis · Riyadh, SAU and 3 other locations · NCT06785779

• Soquelitinib in adults with hidradenitis suppurativa

  This study tests whether oral soquelitinib can help adults with moderate-to-severe hidradenitis suppurativa.

  Recruiting at 9 sites Phase 1 Corvus Pharmaceuticals, Inc. · West Lafayette, Indiana and 10 other locations · NCT07828860

• ORKA-002 versus placebo for moderate-to-severe hidradenitis suppurativa

  A study tests ORKA-002 against placebo in adults with moderate-to-severe hidradenitis suppurativa to see if it helps reduce symptoms.

  Recruiting at 25 sites Phase 2 Oruka Therapeutics, Inc. · Birmingham, Alabama and 24 other locations · NCT07783542

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.